Anti-PD-L1-TGFb antibody (M7824) in advanced non-small cell lung cancer

抗 PD-L1-TGFb 抗体 (M7824) 在晚期非小细胞肺癌中的应用

• 批准号: 10926393
• 负责人: Arun Rajan
• 金额: $ 13.26万
• 依托单位: DIVISION OF BASIC SCIENCES - NCI
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10926393
• 关键词: American Society of Clinical Oncology; Antibodies; Biological Markers; Blood specimen; Combination immunotherapy; Correlative Study; Drug usage; Enrollment; Evaluation; Frequencies; Immunotherapy; Manuscripts; Monoclonal Antibodies; Necrosis; Non-Small-Cell Lung Carcinoma; Patients; Preparation; Sampling; Solid Neoplasm; TGFB1 gene; Tissue Sample; anti-PD-1; cancer biomarkers; cohort; experience; immune activation; immune-related adverse events; meetings; partial response; participant enrollment; phase I trial; posters; programmed cell death ligand 1; response; tumor; virtual

M7824 is a bifunctional monoclonal antibody targeting programmed death ligand 1 (PD-L1) and transforming growth factor-beta. The use of this drug represents a form of combination immunotherapy. Fourteen patients with advanced NSCLC have enrolled in the biomarker cohort. This includes 8 patients who have previously received immunotherapy and 6 patients who have not received immunotherapy. Three (21%) patients experienced a partial response including 2 (33%) of 6 patients who had not received immunotherapy previously. Treatment was well tolerated and the frequency of immune-related adverse events was not higher than that observed with anti-PD-1/PD-L1 monotherapy. Analysis of tissue and blood samples demonstrate tumor necrosis and immune activation. A poster based on this study was presented at the Virtual Annual Meeting of the American Society of Clinical Oncology (ASCO) in June 2020 and a manuscript is in preparation.

M7824是一种双功能单克隆抗体，靶向编程死亡配体1（PD-L1）和转化生长因子-Beta。该药物的使用代表了一种联合免疫疗法的形式。 14例晚期NSCLC患者已入学生物标志物队列。这包括8例以前接受免疫疗法的患者和6例未接受免疫疗法的患者。三名（21％）患者的部分反应，包括6例以前未接受免疫疗法的患者中有2例（33％）。治疗良好，免疫相关不良事件的频率不高于抗PD-1/PD-1/PD-L1单药治疗的频率。组织和血液样品的分析表明肿瘤坏死和免疫激活。 2020年6月，在美国临床肿瘤学会（ASCO）的虚拟年会上介绍了基于这项研究的海报，并正在准备手稿。

项目成果

Comparison of Eight Technologies to Determine Genotype at the UGT1A1 (TA)n Repeat Polymorphism: Potential Clinical Consequences of Genotyping Errors?

• DOI: 10.3390/ijms21030896
• 发表时间: 2020-02-01
• 期刊: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
• 影响因子: 5.6
• 作者: Sissung, Tristan M.;Barbier, Roberto H.;Figg, William D.
• 通讯作者: Figg, William D.